Parkinson DiseasePhase 1NCT05274568
Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
A Phase 1 study testing [18F]UCB-2897 in people with Parkinson Disease and Multisystem Atrophy, run by Invicro at 1 site in United States.
Trial summary
The overall goal of this protocol is to: Evaluate [18F]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: Confirm a specific α -synuclein signal with [18F]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers Secondary and exploratory objectives are: Determine the… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Parkinson Disease, Multisystem Atrophy, Healthy Volunteer
- What is being tested?
- [18F]UCB-2897
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jan 2022to 25 Oct 2023
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participant is able to provide informed consent, which must be obtained before any study procedures are performed.
- Female participants must not be of childbearing potential, or if they are of childbearing potential must agree to use contraception and not donate eggs.
- A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (ie, removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the principal investigator (PI) (eg, Müllerian agenesis).
- Women of childbearing potential must commit to remain abstinent (refrain from heterosexual intercourse) or use 2 forms of birth control, 1 of which is a barrier contraception method, for the duration of the study and 30 days after study completion. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.
- Women of childbearing potential must commit to not donate ova for the duration of the study and 30 days after study completion.
- Male participants with partners of childbearing potential must commit to the use of 2 methods of contraception, 1 of which is a barrier method for male participants for the study duration and 90 days after study completion.
Show all 31Show fewer
- Male participants must not donate sperm for the study duration and for 90 days after study completion.
- Willing and able to cooperate with study procedures.
- For participants who will have arterial cannulation performed, adequate circulation to the hand for safe placement of arterial line (as determined by Allen's test) and blood clotting (Prothrombin Time [PT] and Partial Thromboplastin Time [PTT]).
- If participant takes bupropion, participant must agree to hold this medication for at least 12 hours prior to DaTscan imaging (if performed).
- OTC medication (except acetaminophen), herbal supplements, dietary supplements, or vitamins approved by the Investigator, must be stable within 2 weeks prior to initial dosing.
- Additional inclusion criteria for participants with MSA:
- Males and females aged ≥ 50 years.
- Diagnosis of probable MSA, according to Consensus Clinical Diagnostic Criteria for MSA and a consistent MRI scan performed either at Screening or previously acquired.
- Evidence of dopamine transporter (DaT) deficit on DaTscan performed either as part of Screening or previously acquired.
- Medications taken for symptomatic treatment must be maintained on a stable dosage regimen for at least 30 days before Screening Visit.
- Ability to tolerate lying in the scanner for up to 2 hours, without excessive head or jaw tremor or dyskinesia sufficient to cause significant motion artifact on the PET scans.
- Prescription drugs approved by the Investigator must be stable within 4 weeks prior to initial dosing.
- Additional inclusion criteria for participants with PD:
- Males and females aged ≥ 50 years.
- Clinical diagnosis of PD (early, moderate, or severe) for > 6 years, according to medical history, and L-DOPA responsive.
- Evidence of DaT deficit on DaTscan performed either as part of Screening or previously acquired.
- Medications taken for symptomatic treatment must be maintained on a stable dosage regimen for at least 30 days before Screening Visit.
- Ability to tolerate lying in the scanner for up to 2 hours, without excessive head or jaw tremor or dyskinesia sufficient to cause significant motion artifact on the PET scans.
- Prescription drugs approved by the Investigator must be stable within 4 weeks prior to initial dosing.
- Additional inclusion criteria for healthy volunteers:
- Males and females aged ≥18 years.
- Healthy with no clinically relevant finding on physical examination at Screening.
- No family history of α-synucleinopathy, including PD or other early-onset neurological disease associated with dementia.
- No personal history of clinically significant neurologic and/or psychiatric disorders.
- No cognitive impairment as judged by the Investigator.
Who cannot join
- Pregnant, lactating or breastfeeding.
- Current or prior history of any alcohol or drug abuse in the past 2 years to be verified by urine drug screen.
- Laboratory tests with clinically significant abnormalities and/or clinically significant unstable medical illness.
- History of immunodeficiency diseases, including a positive HIV test result.
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody test result.
- Known history of hypersensitivity, including hypersensitivity to the active substances used for DaTscan, [18F]UCB2897, and/or [18F]florbetapir or derivatives, or to any of the associated excipients.
Show all 26Show fewer
- Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease.
- Unsuitable veins for repeated venipuncture.
- Are claustrophobic or otherwise unable to tolerate the imaging procedure.
- MRI with clinically significant structural abnormalities, other than those expected for MSA or PD for those participants.
- Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, central nervous system (CNS) aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI.
- Participant has received an investigational drug within 30 days or five half-lives prior to Day 1, whichever is longer.
- Participant has received treatment with a drug, antibody or vaccine targeting α-synuclein.
- Prior participation in other research protocols, clinical care, or occupational exposure during the past year that would result in radiation exposure to an effective radiation dose exceeding the acceptable annual limit established by the US Federal Guidelines (effective dose of 50 mSv, including the procedures in this clinical protocol).
- For participants receiving DaTscan imaging, ongoing treatment with methylphenidate, modafinil, metoclopramide, alpha methyldopa, reserpine, or amphetamine derivative is prohibited 24 hours or during a period corresponding to 5 half-lives of the compound, whichever longer, prior to DaTscan imaging.
- For participants who will have arterial blood sampling, treatment with any antihemostasis medication (eg, warfarin, heparin, thrombin inhibitors, Factor Xa inhibitors, streptokinase, urokinase, tissue plasminogen activators) within 2 weeks of the planned arterial cannula placement.
- Participant is, in the opinion of the Investigator, unsuitable in any other way to participate in this study.
- Additional exclusion criteria for healthy volunteers:
- BMI < 16 or > 35.
- The participant is currently exposed to nicotine products or had regular nicotine exposure within a six-month period, to be verified by urine cotinine screening.
- Use of any prescription drugs (except approved forms of birth control) or herbal supplements, within 4 weeks prior to Screening.
- Additional exclusion criteria for participants with MSA:
- Evidence of early frequent falls or eye movement abnormalities consistent with progressive supranuclear palsy (PSP).
- Additional exclusion criteria for participants with PD:
- The participant is currently exposed to nicotine products or had regular nicotine exposure within a six-month period, to be verified by urine cotinine screening.
- Evidence of early frequent falls or eye movement abnormalities consistent with PSP.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein by [18F]UCB-2897 in Participants With Parkinson's Disease or Multi-system Atrophy
The overall goal of this protocol is to:
Evaluate [18F]UCB-2897 as an α-synuclein targeted radiopharmaceutical.
The primary objective is:
- Confirm a specific α -synuclein signal with [18F]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers
Secondary and exploratory objectives are:
- Determine the safety and tolerability of microdose [18F]UCB-2897
- Evaluate preliminary dosimetry of [18F]UCB-2897
Additional exploratory objectives are:
- Determine the pharmacokinetics / metabolism of [18F]UCB-2897
- Determine the optimal imaging protocol for [18F]UCB-2897
Read the detailed description
This is a first in human [FiH], open-label study to assess the imaging characteristics, kinetics, and safety of [18F]UCB-2897 in participants with MSA, participants with PD, and healthy participants. Up to 2 participants with MSA, up to 8 participants with PD, and up to 5 healthy volunteers will be enrolled from the available database at Invicro, through advertising, and through physician referral. Participants will be enrolled in 2 parts that may be run concurrently: Part A (up to 2 participants with PD and up to 2 participants with MSA) and Part B (up to 6 participants with PD and up to 5 healthy volunteers). Data will be reviewed on an ongoing basis throughout the study, at least at the end of Part A.
All participants will attend the following (with exceptions noted):
- Screening
- [18F]UCB-2897 positron emission tomography (PET) Imaging Visit (including brain PET imaging or whole-body PET imaging)
- Follow-up Phone Call
- Amyloid PET Imaging Visit (not performed for all participants)
- DaTscan single photon emission computed tomography (SPECT) Imaging Visit (not performed for all participants)
During Screening, participants will undergo assessments to confirm study eligibility, including an MRI scan (unless a previously acquired approved scan is available) for participants who will have brain PET imaging. Participants with MSA and PD will also have a DaTscan SPECT scan during Screening (unless a previously acquired approved scan is available).
Within 4 weeks of the start of Screening, participants will attend a [18F]UCB-2897 PET Imaging Visit. Participants with MSA, participants with PD, and up to 2 healthy volunteers will undergo brain PET imaging, including one injection of [18F]UCB-2897, one brain PET scan lasting up to 2 hours, and arterial blood sampling. If the participant does not consent to arterial blood sampling or the study team deems it appropriate based on emerging data, venous blood samples may be collected in lieu of arterial blood samples. Brain PET imaging and blood data will be used to assess α-synuclein binding by [18F]UCB-2897. Up to 3 healthy volunteers will undergo whole-body PET imaging assessments, including one injection of [18F]UCB-2897, a series of whole-body PET scans lasting up to 6 hours, and urine collection. Whole-body PET imaging and urine samples will be assessed for a preliminary evaluation of [18F]UCB-2897 dosimetry. During PET imaging (both brain and whole-body), safety assessments will be performed to evaluate the safety and tolerability of [18F]UCB-2897, including ECGs, physical and neurological examinations, clinical laboratory samples, and vital sign measurements.
A Follow-up Phone Call to the participant will be conducted 4 days (± 2 days) post-injection of [18F]UCB-2897 to confirm participant well-being and to collect information about any new adverse events (AEs).
If the study team considers that further investigation on potential cross-binding with beta (β)-amyloid is needed, participants with MSA or PD will attend an Amyloid PET Imaging Visit and have amyloid PET imaging performed with an approved amyloid tracer (unless a previously acquired approved scan is available). Additionally, if needed for further interpretation of data, healthy volunteers who received brain PET imaging may have a DaTscan SPECT scan (unless a previously acquired approved scan is available).
When the participant completes his or her final study visit, the participant will be formally released from the study.
- Conditions
- Parkinson Disease, Multisystem Atrophy, Healthy Volunteer
- Being tested
- [18F]UCB-2897
- Medical subject headings
- Parkinson Disease, Multiple System Atrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
[18F]UCB-2897Drug
Investigational Agent:
[18F]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product [18F]UCB2897is delivered in normal saline (0.9 % sodium chloride [NaCl]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. [18F]UCB2897 will be stored at ambient temperature in its original container.
| Study group | Role | What they receive |
|---|---|---|
| [18F]UCB-2897 | Experimental | Administration of Investigational Agent:
Study center personnel will administer [18F]UCB-2897 as an IV injection. Prior to PET imaging, participants will have an IV catheter (for radiopharmaceutical administration) inserted according to standard clinical practice. Each participant will receive a single injection of [18F]UCB-2897. [18F]UCB-2897 will be injected IV at a dose of not more than 10 mCi, with a maximum mass dose of 10 μg and maximum volume of 10 mL. The injection will be followed by a 10 mL saline flush. Qualified study staff will accompany participants during PET imaging procedures. Receives: Drug: [18F]UCB-2897 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantitative analysis of [18F]UCB-2897 brain PET scans
[18F]UCB-2897 uptake and kinetics will be examined in the MSA, PD, and healthy volunteer groups descriptively and quantitatively to describe the α-synuclein deposition as measured by [18F]UCB-2897 across multiple brain regions.
Measured: Day 1: PET Imaging Visit
Whole-body Biodistribution Outcome Measures
For whole-body biodistribution, total source organ counts over time based on an individualized VOI template will be used to determine radiation absorbed dose estimates and whole-body effective doses based on the MIRD methodology.
Measured: [18F]UCB-2897 PET Imaging Visit
Safety Outcome Measures
Safety will be evaluated throughout the study. Safety will be evaluated by assessing incidence and severity of AEs, results from measurements of vital signs and ECGs, results from measurements for parameters of hematology, clinical chemistry, and urinalysis.
Measured: Screening, pre-injection, and at the completion of imaging
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2022
- Study start31 Jan 2022
- Primary completion25 Oct 2023
- Study completion25 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Invicro
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- David Russell, MD, Ph.D, Principal investigator, Principal InvestigatorJoyce Gibbons, PA-C, Principal investigator, Sub-InvestigatorAmy Knorr, MD, Principal investigator, Sub-Investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05274568
- Sponsor's protocol ID
- 10616
- Status last verified
- Feb 2025
- First submitted
- 1 Feb 2022
- Last updated
- 20 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein by [18F]UCB-2897 in Participants With Parkinson's Disease or Multi-system Atrophy
- ClinicalTrials.gov ID
- NCT05274568
- Acronym / sponsor ID
- 10616
- Conditions
- Parkinson Disease, Multisystem Atrophy, Healthy Volunteer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- InvicroUniversity, hospital or other
- Study start
- 31 Jan 2022 (actual)
- Primary completion
- 25 Oct 2023 (actual)
- Study completion
- 25 Oct 2023 (actual)
- First posted
- 10 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall goal of this protocol is to:
Evaluate [18F]UCB-2897 as an α-synuclein targeted radiopharmaceutical.
The primary objective is:
- Confirm a specific α -synuclein signal with [18F]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers
Secondary and exploratory objectives are:
- Determine the safety and tolerability of microdose [18F]UCB-2897
- Evaluate preliminary dosimetry of [18F]UCB-2897
Additional exploratory objectives are:
- Determine the pharmacokinetics / metabolism of [18F]UCB-2897
- Determine the optimal imaging protocol for [18F]UCB-2897
Detailed description
This is a first in human [FiH], open-label study to assess the imaging characteristics, kinetics, and safety of [18F]UCB-2897 in participants with MSA, participants with PD, and healthy participants. Up to 2 participants with MSA, up to 8 participants with PD, and up to 5 healthy volunteers will be enrolled from the available database at Invicro, through advertising, and through physician referral. Participants will be enrolled in 2 parts that may be run concurrently: Part A (up to 2 participants with PD and up to 2 participants with MSA) and Part B (up to 6 participants with PD and up to 5 healthy volunteers). Data will be reviewed on an ongoing basis throughout the study, at least at the end of Part A.
All participants will attend the following (with exceptions noted):
- Screening
- [18F]UCB-2897 positron emission tomography (PET) Imaging Visit (including brain PET imaging or whole-body PET imaging)
- Follow-up Phone Call
- Amyloid PET Imaging Visit (not performed for all participants)
- DaTscan single photon emission computed tomography (SPECT) Imaging Visit (not performed for all participants)
During Screening, participants will undergo assessments to confirm study eligibility, including an MRI scan (unless a previously acquired approved scan is available) for participants who will have brain PET imaging. Participants with MSA and PD will also have a DaTscan SPECT scan during Screening (unless a previously acquired approved scan is available).
Within 4 weeks of the start of Screening, participants will attend a [18F]UCB-2897 PET Imaging Visit. Participants with MSA, participants with PD, and up to 2 healthy volunteers will undergo brain PET imaging, including one injection of [18F]UCB-2897, one brain PET scan lasting up to 2 hours, and arterial blood sampling. If the participant does not consent to arterial blood sampling or the study team deems it appropriate based on emerging data, venous blood samples may be collected in lieu of arterial blood samples. Brain PET imaging and blood data will be used to assess α-synuclein binding by [18F]UCB-2897. Up to 3 healthy volunteers will undergo whole-body PET imaging assessments, including one injection of [18F]UCB-2897, a series of whole-body PET scans lasting up to 6 hours, and urine collection. Whole-body PET imaging and urine samples will be assessed for a preliminary evaluation of [18F]UCB-2897 dosimetry. During PET imaging (both brain and whole-body), safety assessments will be performed to evaluate the safety and tolerability of [18F]UCB-2897, including ECGs, physical and neurological examinations, clinical laboratory samples, and vital sign measurements.
A Follow-up Phone Call to the participant will be conducted 4 days (± 2 days) post-injection of [18F]UCB-2897 to confirm participant well-being and to collect information about any new adverse events (AEs).
If the study team considers that further investigation on potential cross-binding with beta (β)-amyloid is needed, participants with MSA or PD will attend an Amyloid PET Imaging Visit and have amyloid PET imaging performed with an approved amyloid tracer (unless a previously acquired approved scan is available). Additionally, if needed for further interpretation of data, healthy volunteers who received brain PET imaging may have a DaTscan SPECT scan (unless a previously acquired approved scan is available).
When the participant completes his or her final study visit, the participant will be formally released from the study.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| [18F]UCB-2897 | Experimental | Drug: [18F]UCB-2897Administration of Investigational Agent: Study center personnel will administer [18F]UCB-2897 as an IV injection. Prior to PET imaging, participants will have an IV catheter (for radiopharmaceutical administration) inserted according to standard clinical practice. Each participant will receive a single injection of [18F]UCB-2897. [18F]UCB-2897 will be injected IV at a dose of not more than 10 mCi, with a maximum mass dose of 10 μg and maximum volume of 10 mL. The injection will be followed by a 10 mL saline flush. Qualified study staff will accompany participants during PET imaging procedures. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (31 listed)
- Participant is able to provide informed consent, which must be obtained before any study procedures are performed.
- Female participants must not be of childbearing potential, or if they are of childbearing potential must agree to use contraception and not donate eggs.
- Male participants with partners of childbearing potential must commit to the use of 2 methods of contraception, 1 of which is a barrier method for male participants for the study duration and 90 days after study completion.
- Male participants must not donate sperm for the study duration and for 90 days after study completion.
- Willing and able to cooperate with study procedures.
Key exclusion criteria (26 listed)
- Pregnant, lactating or breastfeeding.
- Current or prior history of any alcohol or drug abuse in the past 2 years to be verified by urine drug screen.
- Laboratory tests with clinically significant abnormalities and/or clinically significant unstable medical illness.
- History of immunodeficiency diseases, including a positive HIV test result.
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody test result.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| [18F]UCB-2897Investigational Agent: [18F]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product [18F]UCB2897is delivered in normal saline (0.9 % sodium chloride [NaCl]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. [18F]UCB2897 will be stored at ambient temperature in its original container. | Drug | [18F]UCB-2897 |
Primary outcome
Quantitative analysis of [18F]UCB-2897 brain PET scans
Time frame: Day 1: PET Imaging Visit
[18F]UCB-2897 uptake and kinetics will be examined in the MSA, PD, and healthy volunteer groups descriptively and quantitatively to describe the α-synuclein deposition as measured by [18F]UCB-2897 across multiple brain regions.
Whole-body Biodistribution Outcome Measures
Time frame: [18F]UCB-2897 PET Imaging Visit
For whole-body biodistribution, total source organ counts over time based on an individualized VOI template will be used to determine radiation absorbed dose estimates and whole-body effective doses based on the MIRD methodology.
Safety Outcome Measures
Time frame: Screening, pre-injection, and at the completion of imaging
Safety will be evaluated throughout the study. Safety will be evaluated by assessing incidence and severity of AEs, results from measurements of vital signs and ECGs, results from measurements for parameters of hematology, clinical chemistry, and urinalysis.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Russell, MD, Ph.D principal investigator
Principal Investigator
Joyce Gibbons, PA-C principal investigator
Sub-Investigator
Amy Knorr, MD principal investigator
Sub-Investigator
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing [18F]UCB-2897 in people with Parkinson Disease and Multisystem Atrophy, run by Invicro at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 31 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantitative analysis of [18F]UCB-2897 brain PET scans (time frame: Day 1: PET Imaging Visit). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2025.